Raquel Lidon-Vicente
Zaragoza, AR, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Real-World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry.
Journal: United European gastroenterology journal
Published: February 01, 2026
Impact of celiac disease on the clinical course of inflammatory bowel disease: CEL_EII study by GETECCU.
Journal: Therapeutic advances in gastroenterology
Published: January 28, 2026
External validation of population pharmacokinetic models of adalimumab in adult patients with inflammatory bowel disease: towards model-informed precision dosing.
Journal: Journal of pharmacokinetics and pharmacodynamics
Published: January 22, 2026
Predictors of Steroid Failure and Outcomes of Rescue Therapy in Severe ICI-Induced Colitis: A Multicenter Study from GETECCU.
Journal: Digestive diseases and sciences
Published: January 05, 2026
Clinical, Endoscopic, and Histological Characteristics of Severe Immune Checkpoint Inhibitor-Induced Colitis.
Journal: Journal of clinical medicine
Published: September 24, 2025
Real-world effectiveness of vedolizumab in refractory pouchitis: a focus on biomarker changes during intravenous to subcutaneous transition (POUCHIVED study).
Journal: Frontiers in immunology
Published: September 17, 2025
Translation and psychometric evaluation of the Spanish version of the Inflammatory Bowel Disease Knowledge (IBD-KNOW) questionnaire.
Journal: Gastroenterologia y hepatologia
Published: August 21, 2025
Patients Included in Clinical Trials of Biological Drugs for Inflammatory Bowel Disease Do Not Represent the Real-World Population.
Journal: The American journal of gastroenterology
Published: February 10, 2025
Complications and survival following percutaneous endoscopic gastrostomy tube placement.
Journal: Revista espanola de enfermedades digestivas
Published: May 20, 2024
Impact of mesalazine on the response to COVID-19 vaccination in patients with inflammatory bowel disease: Results of a prospective multicentre study of GETECCU (VACOVEII study).
Journal: Gastroenterologia y hepatologia
Published: November 09, 2023
A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study).
Journal: Gastroenterologia y hepatologia
Published: September 07, 2023
HLA-DQA1*05 Was Not Associated With Primary Nonresponse or Loss of Response to First Anti-TNF in Real-World Inflammatory Bowel Disease Patients.
Journal: Inflammatory bowel diseases
Published: March 24, 2023
Last Updated: 09/26/2026